Here is a brief preview of this blast: On Friday, June 23, the CHMP meeting highlights were released. Of note, Abecma (BMS’s BCMA CAR-T) was absent from the CHMP highlights implying that it has received a Request for Supplementary Information (RSI) for its assessment in ≥3L MM. Moreover, recall that Carvykti (JNJ / Legend’s BCMA CAR-T) was listed as ‘Start of Procedure’ under ‘Type II Variations: Extension of Indications’ to expand its label to ≥2L MM on Monday’s CHMP agenda. Below, Celltelligence provides insights on the June CHMP meeting with updated EU regulatory timelines for both cell therapies.